The Life Sciences Law Firm Index: Patent Category Update
Which law firms were at the top of our patent category through Q3 2017?
Wilson Sonsini Tops Life Sciences Law Firm Index For 2nd Straight Year
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Legal Is Changing. And NeoSummit Is Where The Future Is Being Built.
Legal and operational leaders are gathering May 6–7 in Fort Lauderdale to confront the questions the industry hasn't answered—with a keynote from Amanda Knox setting the tone.
Finding A Way Through A Tight Deal Space
Leaders of WilmerHale’s life sciences practice share trends they see regarding acquisitions and initial public offerings.
Navigating The Life Science M&A Savannah
What does the market for life sciences M&A look like right now?
Collaboration At Fenwick & West Steers Firm Through Complex Deals
What does the market for life sciences companies look like right now?
Newly United Arnold & Porter Kaye Scholer Surveys Changed Life Sciences Deal Environment
Experts offer their takes on the developing dealmaking environment in the early days of the Trump Administration.
Protégé™ In CourtLink® Explains The Whole Case Faster
Designed to reduce manual docket work by prioritizing what litigators need most: on-demand full docket summarization that explains the whole case to date, followed by on-demand document summaries for filing triage, and AI-powered natural language searching for faster search and retrieval.
The Life Sciences Law Firm Index: Patent Category Update
Which law firms were at the top of our patent category through Q1 2016?
Aggregate Spend Goes Global
As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift through the growing maze of rules and regulations across the U.S.
Friends And Family (Offices) Step In To Funding Drought
Not too long ago, it didn’t take much for someone with an idea for a new medical device to rake in the early-stage funding.
M&A: The Last Refuge For Biotechs Seeking Funding
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind. But when the going gets tough, the tough consider strategic alternatives...
Has Legal Industry Upheaval Changed Your Career Goals?
We'd love to hear your thoughts. Enter for a chance to win a $250 gift card.